Shanghai – October 15, 2026 -- WuXi XDC (2268.HK) has won "Best CDMO" at the 2026 World ADC Awards for the fourth consecutive year and "Best CRO" for the second, making it the only contract research, development and manufacturing organization (CRDMO) to take both titles two years running.

Shanghai – September 19, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.